151751-Najiba-Chargi

207 Systemic therapy: skeletal muscle mass and chemoradiotherapy Table 4. Univariate and multivariate analysis for overall survival Univariate analysis Multivariate analysis Hazard Ratio (95% CI) p-value Hazard Ratio (95% CI) p-value Gender Male Female Ref 1.06 (0.57 - 1.98) 0.86 Age at diagnosis (years) 1.02 (0.97 – 1.06) 0.58 BMI at diagnosis (kg/m 2 ) 0.93 (0.87 – 0.99) 0.03 0.94 (0.88 - 1.00) 0.07 Tumor site Oropharynx HPV+ Oropharynx HPV-/unknown Hypopharynx Larynx Excluded* Ref 1.86 (0.74 - 4.69) 1.46 (0.81 - 2.61) 0.19 0.21 AJCC stage 2 and 3 4 Ref 3.57 (1.79 - 7.14) <0.01 Ref 3.40 (1.69 - 6.81) <0.01 CDLT No Yes Ref 2.11 (1.15 - 3.89) 0.02 Ref 2.10 (1.13 - 3.90) 0.02 Low SMM No Yes Ref 1.23 (0.71 - 2.16) 0.46 ECE No Yes Ref 1.10 (0.55 - 2.19) 0.80 ACE-27 score 0 1 or 2 Ref 0.79 (0.41 - 1.53) 0.48 Bold indicates a significant difference between groups. * HPV-related oropharyngeal cancer: HR 0.07 (95% CI 0.02 - 0.31], p < 0.01. SURVIVAL ANALYSIS Table 4 shows univariate and multivariate Cox regression analysis for OS in HPV-negative patients or patients with unknown HPV-status (n=112). In univariate Cox regression analysis, by far the most important prognosticator was HPV-status of the tumor; with patients with HPV-related oropharyngeal cancer having a better prognosis than other patients in this cohort (HR 0.07 [95%CI 0.02 - 0.31], p < 0.01). In univariate Cox regression analysis, low SMMwas not a significant prognosticator (HR 1.23 [95% CI 0.71 - 2.16], p = 0.46) for OS, as visualized in figure 2. In contrast, the occurrence of CDLT was significantly associated with a decreased OS (HR 2.11 [95% CI 1.15 - 3.89], p = 0.02), as visualized in figure 3. Other significant prognosticators for OS were AJCC stage IV disease (HR 3.57 [95% CI 1.79 - 7.14), p < 0.01) and BMI (HR 0.93 [95% CI 0.87 - 0.99], p = 0.03), with a higher BMI being associated with significantly better OS. In 11